No, there is no FDA-approved generic for Jardiance (empagliflozin) currently available in the United States. The drug is still under patent protection by Boehringer Ingelheim, with a generic not expected before the mid-to-late 2020s. If cost is the main concern, Medicare Part D negotiation (effective 2026), manufacturer savings programs, and GoodRx discounts are the main legitimate options — but talk to your doctor before switching away from Jardiance, because its heart and kidney benefits are not shared by cheaper non-SGLT2 drugs.
Why There Is No Generic Yet
When a drug is approved, it enjoys a combination of patent protection and regulatory exclusivity that prevents generic manufacturers from selling copies. Jardiance (empagliflozin) was FDA-approved in 2014 and holds multiple patents covering the compound, specific formulations, and methods of use for diabetes, cardiovascular indications, and heart failure. Boehringer Ingelheim and Eli Lilly (the co-marketer) have also pursued pediatric exclusivity extensions.
Generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with Paragraph IV challenges — claims that the brand patents are invalid or not infringed — which have led to patent litigation. The outcome of that litigation and any resulting settlement will determine the earliest possible generic entry date.
Expected Timeline (As Best Known)
| Milestone | Status / Expected |
|---|---|
| Original FDA approval | August 2014 |
| Core compound patent expiration | Approximately 2025 (subject to extensions) |
| Additional use / formulation patents | Several extend through 2028 or later |
| Medicare negotiated price effective | January 2026 |
| Likely first generic launch window (US) | 2025 to 2028 (uncertain) |
Patent litigation outcomes and settlements between Boehringer and generic manufacturers can move these dates either direction. Check current FDA Orange Book listings and Paragraph IV litigation status for the latest picture.
The Broader SGLT2 Class: Still All Brand-Name
| Drug | Generic Name | FDA Approval | Generic Available? |
|---|---|---|---|
| Jardiance | Empagliflozin | 2014 | No |
| Farxiga | Dapagliflozin | 2014 | No |
| Invokana | Canagliflozin | 2013 | No |
| Steglatro | Ertugliflozin | 2017 | No |
Switching among SGLT2 inhibitors does not help with cost because they are all still brand-name.
Why Jardiance Is Expensive
Beyond patent protection, Jardiance’s list price reflects its clinical value. Three trials — EMPA-REG OUTCOME (cardiovascular), EMPA-KIDNEY (chronic kidney disease), and EMPEROR-Reduced / EMPEROR-Preserved (heart failure) — demonstrated mortality and morbidity benefits that go beyond glucose control. Payers and patients are paying for these outcome benefits, not just glucose lowering.
Ways to Lower Jardiance Cost Now
1. Manufacturer Savings Card
Boehringer Ingelheim and Lilly have operated Jardiance savings programs for patients with commercial insurance, sometimes reducing copays to $10 per month for a limited time. These are not available to Medicare, Medicaid, or uninsured patients. Eligibility and dollar caps change annually.
2. Patient Assistance Programs
The Lilly Cares Foundation and Boehringer Ingelheim Cares Foundation provide free or heavily discounted Jardiance to uninsured or underinsured patients meeting income criteria. Applications require clinician signature.
3. Medicare Part D Negotiated Price (2026)
Jardiance was among the first 10 drugs selected for Medicare Part D price negotiation under the Inflation Reduction Act. The negotiated “Maximum Fair Price” takes effect January 2026 and should significantly reduce Medicare beneficiaries’ out-of-pocket cost. Commercial plans are not required to use the negotiated rate.
4. GoodRx / Cash Discount Cards
Without insurance, cash prices with a discount card can sometimes be lower than full retail. Always compare prices across pharmacies and check manufacturer coupons first.
5. 90-Day Fills via Mail Order
Many commercial plans offer a two-copay price for a 90-day supply via mail order vs three copays for three 30-day fills at retail.
Non-SGLT2 Alternatives — and Why They Are Not the Same
| Purpose | Generic Alternative | Trade-Offs vs Jardiance |
|---|---|---|
| Glucose control | Metformin, glipizide, pioglitazone | Cheap; no SGLT2-class CV, kidney, or HF benefits |
| Kidney protection (diabetes) | ACE inhibitor (lisinopril) or ARB (losartan) | Complementary; usually added to — not replacing — SGLT2 |
| Heart failure | ACEi/ARB, beta-blocker, MRA (spironolactone), ARNI (sacubitril-valsartan) | Complementary; SGLT2 added on top in modern HF care |
| Cardiovascular risk | Statins, aspirin (selected) | Different mechanisms; usually used with SGLT2, not instead of |
Most of these generics add to SGLT2 benefits rather than replace them. Dropping Jardiance to save money may cost you cardiovascular, kidney, or heart-failure protection that the cheaper drug cannot provide.
Who Should Stay on Jardiance Even if Cost Is a Problem
- Patients with type 2 diabetes and established cardiovascular disease
- Patients with type 2 diabetes and chronic kidney disease (albuminuria, reduced eGFR)
- Patients with heart failure with reduced or preserved ejection fraction, with or without diabetes
For these patients, Jardiance changes major clinical outcomes. Work with your prescriber on financial assistance rather than stopping the drug.
Who Might Reasonably Switch With Clinician Guidance
- Patients taking Jardiance only for glucose control without the above conditions might be able to switch to or add generic metformin-plus-other-options
- Patients with intolerable side effects (genital yeast infections, volume depletion, ketoacidosis risk)
Any switch needs a clinician conversation to make sure the alternative actually covers your conditions.
Related Reading
For broader context on diabetes drug classes and treatment approaches, see our treatment hub. If you are trying to understand how prediabetes can be reversed, lifestyle changes and weight loss remain the foundation regardless of medication choice.
The Bottom Line
No generic Jardiance exists in the United States today, and the earliest realistic window for one is 2025 to 2028. If you are on Medicare Part D, the 2026 negotiated price will cut your out-of-pocket cost significantly. If you are on commercial insurance, manufacturer savings cards can bring copays down. If cost is a real barrier, talk to your prescriber about patient assistance programs before considering a switch — Jardiance’s cardiovascular, kidney, and heart-failure benefits are not shared by cheaper alternatives.
